Inhibition of microRNA-33b in humanized mice ameliorates nonalcoholic steatohepatitis

The data that support the findings of this study are available from

the corresponding authors upon reasonable request.

Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M, Chen

Y, Zhao X, Schmidl C, Suzuki T, et al (2014) An atlas of active enhancers

across human cell types and tissues. Nature 507: 455–461. doi:10.1038/

nature12787

Supplementary Information

Supplementary Information is available at https://doi.org/10.26508/lsa.

202301902

Acknowledgements

This work was supported by the Ministry of Education, Culture, Sports,

Science and Technology (MEXT) and Japan Society for the Promotion of

Science (JSPS) KAKENHI Grants 17K09860 and 20K08904 (to T Horie), and

17H04177, 17H05599, and 20H03675 (to K Ono), as well as a grant from the Cell

Science Research Foundation (to T Horie). This research was also supported

by AMED under Grant Number 21ym0126013h0001 (to K Ono).

Author Contributions

S Miyagawa: data curation, formal analysis, and investigation.

T Horie: conceptualization, data curation, formal analysis, supervision, funding acquisition, investigation, and writing—original

draft.

T Nishino: data curation and formal analysis.

S Koyama: data curation and formal analysis.

T Watanabe: data curation.

O Baba: investigation.

T Yamasaki: data curation, formal analysis, and investigation.

N Sowa: data curation and formal analysis.

C Otani: data curation and investigation.

K Matsushita: data curation and investigation.

H Kojima: data curation, formal analysis, and investigation.

M Kimura: data curation, formal analysis, and investigation.

Y Nakashima: investigation.

S Obika: data curation and methodology.

Y Kasahara: data curation and methodology.

J Kotera: data curation and methodology.

K Oka: data curation and methodology.

R Fujita: data curation and methodology.

T Sasaki: data curation and methodology.

A Takemiya: data curation and methodology.

K Hasegawa: data curation and investigation.

T Kimura: data curation, supervision, and investigation.

K Ono: conceptualization, formal analysis, supervision, funding

acquisition, validation, investigation, project administration, and

writing—original draft, review, and editing.

Auguet T, Aragones G, Berlanga A, Guiu-Jurado E, Marti A, Martinez S, Sabench

F, Hernandez M, Aguilar C, Sirvent JJ, et al (2016) miR33a/miR33b* and

miR122 as possible contributors to hepatic lipid metabolism in obese

women with nonalcoholic fatty liver disease. Int J Mol Sci 17: 1620.

doi:10.3390/ijms17101620

Azzu V, Vacca M, Kamzolas I, Hall Z, Leslie J, Carobbio S, Virtue S, Davies SE,

Lukasik A, Dale M, et al (2021) Suppression of insulin-induced gene 1

(INSIG1) function promotes hepatic lipid remodelling and restrains

NASH progression. Mol Metab 48: 101210. doi:10.1016/

j.molmet.2021.101210

Beaven SW, Wroblewski K, Wang J, Hong C, Bensinger S, Tsukamoto H,

Tontonoz P (2011) Liver X receptor signaling is a determinant of

stellate cell activation and susceptibility to fibrotic liver disease.

Gastroenterology 140: 1052–1062. doi:10.1053/j.gastro.2010.11.053

Boland ML, Oro D, Tolbol KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE,

Fernandes F, Tovchigrechko A, Veidal SS, et al (2019) Towards a

standard diet-induced and biopsy-confirmed mouse model of nonalcoholic steatohepatitis: Impact of dietary fat source. World J

Gastroenterol 25: 4904–4920. doi:10.3748/wjg.v25.i33.4904

Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR

(1999) Nonalcoholic steatohepatitis: A proposal for grading and

staging the histological lesions. Am J Gastroenterol 94: 2467–2474.

doi:10.1111/j.1572-0241.1999.01377.x

Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De

Paolis P, Capussotti L, Salizzoni M, et al (2002) Expanding the natural

history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to

hepatocellular carcinoma. Gastroenterology 123: 134–140. doi:10.1053/

gast.2002.34168

Caballero F, Fernandez A, De Lacy AM, Fernandez-Checa JC, Caballeria J,

Garcia-Ruiz C (2009) Enhanced free cholesterol, SREBP-2 and StAR

expression in human NASH. J Hepatol 50: 789–796. doi:10.1016/

j.jhep.2008.12.016

Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M,

Sanyal AJ, American Gastroenterological Association, American

Association for the Study of Liver Diseases, et al (2012). The diagnosis

and management of non-alcoholic fatty liver disease: Practice

guideline by the American gastroenterological association, American

association for the study of liver diseases, and American college of

gastroenterology. Gastroenterology 142: 1592–1609. doi:10.1053/

j.gastro.2012.04.001

Chen G, Liang G, Ou J, Goldstein JL, Brown MS (2004) Central role for liver X

receptor in insulin-mediated activation of Srebp-1c transcription and

stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A 101:

11245–11250. doi:10.1073/pnas.0404297101

Copeland NG, Jenkins NA, Court DL (2001) Recombineering: A powerful new

tool for mouse functional genomics. Nat Rev Genet 2: 769–779.

doi:10.1038/35093556

Davalos A, Goedeke L, Smibert P, Ramirez CM, Warrier NP, Andreo U, CireraSalinas D, Rayner K, Suresh U, Pastor-Pareja JC, et al (2011) miR-33a/b

contribute to the regulation of fatty acid metabolism and insulin

signaling. Proc Natl Acad Sci U S A 108: 9232–9237. doi:10.1073/

pnas.1102281108

The authors declare that they have no conflict of interest.

Dorn C, Riener MO, Kirovski G, Saugspier M, Steib K, Weiss TS, Gabele E,

Kristiansen G, Hartmann A, Hellerbrand C (2010) Expression of fatty

acid synthase in nonalcoholic fatty liver disease. Int J Clin Exp Pathol 3:

505–514.

miR-33b inhibition improves NAFLD/NASH

https://doi.org/10.26508/lsa.202301902

Conflict of Interest Statement

Miyagawa et al.

vol 6 | no 8 | e202301902

15 of 17

Erhartova D, Cahova M, Dankova H, Heczkova M, Mikova I, Sticova E, Spicak J,

Seda O, Trunecka P (2019) Serum miR-33a is associated with steatosis

and inflammation in patients with non-alcoholic fatty liver disease

after liver transplantation. PLoS One 14: e0224820. doi:10.1371/

journal.pone.0224820

Ferre P, Foufelle F (2010) Hepatic steatosis: A role for de novo lipogenesis and

the transcription factor SREBP-1c. Diabetes Obes Metab 12: 83–92.

doi:10.1111/j.1463-1326.2010.01275.x

Folch J, Lees M, Stanley GS (1957) A simple method for the isolation and

purification of total lipides from animal tissues. J Biol Chem 226:

497–509. doi:10.1016/s0021-9258(18)64849-5

Gan LT, Van Rooyen DM, Koina ME, McCuskey RS, Teoh NC, Farrell GC (2014)

Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated

mitochondrial injury and is HMGB1 and TLR4-dependent. J Hepatol 61:

1376–1384. doi:10.1016/j.jhep.2014.07.024

Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, Berlakovich G, Fritz J,

Feurstein B, Popp W, Karam V, et al (2019) Outcomes of liver

transplantation for non-alcoholic steatohepatitis: A European liver

transplant registry study. J Hepatol 71: 313–322. doi:10.1016/

j.jhep.2019.04.011

He J, Zhang G, Pang Q, Yu C, Xiong J, Zhu J, Chen F (2017) SIRT6 reduces

macrophage foam cell formation by inducing autophagy and

cholesterol efflux under ox-LDL condition. FEBS J 284: 1324–1337.

doi:10.1111/febs.14055

Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, Kinoshita M,

Kuwabara Y, Marusawa H, Iwanaga Y, et al (2010a) MicroRNA-33

encoded by an intron of sterol regulatory element-binding protein 2

(Srebp2) regulates HDL in vivo. Proc Natl Acad Sci U S A 107:

17321–17326. doi:10.1073/pnas.1008499107

Horie T, Ono K, Nishi H, Nagao K, Kinoshita M, Watanabe S, Kuwabara Y,

Nakashima Y, Takanabe-Mori R, Nishi E, et al (2010b) Acute

doxorubicin cardiotoxicity is associated with miR-146a-induced

inhibition of the neuregulin-ErbB pathway. Cardiovasc Res 87:

656–664. doi:10.1093/cvr/cvq148

Horie T, Baba O, Kuwabara Y, Chujo Y, Watanabe S, Kinoshita M, Horiguchi M,

Nakamura T, Chonabayashi K, Hishizawa M, et al (2012) MicroRNA-33

deficiency reduces the progression of atherosclerotic plaque in

ApoE(−/−) mice. J Am Heart Assoc 1: e003376. doi:10.1161/

jaha.112.003376

Horie T, Nishino T, Baba O, Kuwabara Y, Nakao T, Nishiga M, Usami S, Izuhara

M, Nakazeki F, Ide Y, et al (2014) MicroRNA-33b knock-in mice for an

intron of sterol regulatory element-binding factor 1 (Srebf1) exhibit

reduced HDL-C in vivo. Scientific Rep 4: 5312. doi:10.1038/srep05312

Ioannou GN (2016) The role of cholesterol in the pathogenesis of NASH.

Trends Endocrinol Metab 27: 84–95. doi:10.1016/j.tem.2015.11.008

Karunakaran D, Thrush B, Nguyen MA, Richards L, Geoffrion M, Singaravelu R,

Ramphos E, Shangari P, Ouimet M, Pezacki JP, et al (2015) Macrophage

mitochondrial energy status regulates cholesterol efflux and is

enhanced by anti-miR33 in atherosclerosis. Circ Res 117: 266–278.

doi:10.1161/CIRCRESAHA.117.305624

Kato T, Shimano H, Yamamoto T, Ishikawa M, Kumadaki S, Matsuzaka T,

Nakagawa Y, Yahagi N, Nakakuki M, Hasty AH, et al (2008) Palmitate

impairs and eicosapentaenoate restores insulin secretion through

regulation of SREBP-1c in pancreatic islets. Diabetes 57: 2382–2392.

doi:10.2337/db06-1806

genetically modified mice. J Am Heart Assoc 8: e012609. doi:10.1161/

jaha.119.012609

Lebeaupin C, Vallee D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B (2018)

Endoplasmic reticulum stress signalling and the pathogenesis of

non-alcoholic fatty liver disease. J Hepatol 69: 927–947. doi:10.1016/

j.jhep.2018.06.008

Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS (2002)

Diminished hepatic response to fasting/refeeding and liver X

receptor agonists in mice with selective deficiency of sterol regulatory

element-binding protein-1c. J Biol Chem 277: 9520–9528. doi:10.1074/

jbc.m111421200

Ludwig J, Viggiano TR, McGill DB, Oh BJ (1980) Nonalcoholic steatohepatitis:

Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin

Proc 55: 434–438.

Marquart TJ, Wu J, Lusis AJ, Baldan A (2013) Anti-miR-33 therapy does not alter

the progression of atherosclerosis in low-density lipoprotein

receptor-deficient mice. Arterioscler Thromb Vasc Biol 33: 455–458.

doi:10.1161/atvbaha.112.300639

Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ (1999)

Nonalcoholic fatty liver disease: A spectrum of clinical and

pathological severity. Gastroenterology 116: 1413–1419. doi:10.1016/

s0016-5085(99)70506-8

Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, Kellum J, Warnick R,

Contos MJ, Sanyal AJ (2012) Increased hepatic synthesis and

dysregulation of cholesterol metabolism is associated with the

severity of nonalcoholic fatty liver disease. Cell Metab 15: 665–674.

doi:10.1016/j.cmet.2012.04.004

Morita M, Ohneda O, Yamashita T, Takahashi S, Suzuki N, Nakajima O,

Kawauchi S, Ema M, Shibahara S, Udono T, et al (2003) HLF/HIF-2α is a

key factor in retinopathy of prematurity in association with

erythropoietin. EMBO J 22: 1134–1146. doi:10.1093/emboj/cdg117

Murakami K, Abe T, Miyazawa M, Yamaguchi M, Masuda T, Matsuura T,

Nagamori S, Takeuchi K, Abe K, Kyogoku M (1995) Establishment of a

new human cell line, LI90, exhibiting characteristics of hepatic Ito (fatstoring) cells. Lab Invest 72: 731–739.

Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM

(2010) MicroRNA-33 and the SREBP host genes cooperate to control

cholesterol homeostasis. Science 328: 1566–1569. doi:10.1126/

science.1189123

Nishiga M, Horie T, Kuwabara Y, Nagao K, Baba O, Nakao T, Nishino T, Hakuno

D, Nakashima Y, Nishi H, et al (2017) MicroRNA-33 controls adaptive

fibrotic response in the remodeling heart by preserving lipid

raft cholesterol. Circ Res 120: 835–847. doi:10.1161/

circresaha.116.309528

Nishino T, Horie T, Baba O, Sowa N, Hanada R, Kuwabara Y, Nakao T, Nishiga M,

Nishi H, Nakashima Y, et al (2018) SREBF1/MicroRNA-33b Axis exhibits

potent effect on unstable atherosclerotic plaque formation in vivo.

Arterioscler Thromb Vasc Biol 38: 2460–2473. doi:10.1161/

atvbaha.118.311409

Ouimet M, Ediriweera HN, Gundra UM, Sheedy FJ, Ramkhelawon B, Hutchison

SB, Rinehold K, van Solingen C, Fullerton MD, Cecchini K, et al (2015)

MicroRNA-33-dependent regulation of macrophage metabolism

directs immune cell polarization in atherosclerosis. J Clin Invest 125:

4334–4348. doi:10.1172/jci81676

Pettinelli P, Videla LA (2011) Up-regulation of PPAR-gamma mRNA expression

in the liver of obese patients: An additional reinforcing lipogenic

mechanism to SREBP-1c induction. Mol Endocrinol 25: 547–1430.

doi:10.1210/mend.25.3.zmg547

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW,

Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al (2005)

Design and validation of a histological scoring system for

nonalcoholic fatty liver disease. Hepatology 41: 1313–1321.

doi:10.1002/hep.20701

Powell EE, Wong VW, Rinella M (2021) Non-alcoholic fatty liver disease. The

Lancet 397: 2212–2224. doi:10.1016/s0140-6736(20)32511-3

Koyama S, Horie T, Nishino T, Baba O, Sowa N, Miyasaka Y, Kuwabara Y, Nakao

T, Nishiga M, Nishi H, et al (2019) Identification of differential roles of

MicroRNA-33a and -33b during atherosclerosis progression with

Price NL, Zhang X, Fernandez-Tussy P, Singh AK, Burnap SA, Rotllan N,

Goedeke L, Sun J, Canfran-Duque A, Aryal B, et al (2021) Loss of hepatic

miR-33 improves metabolic homeostasis and liver function without

miR-33b inhibition improves NAFLD/NASH

https://doi.org/10.26508/lsa.202301902

Miyagawa et al.

vol 6 | no 8 | e202301902

16 of 17

altering body weight or atherosclerosis. Proc Natl Acad Sci U S A 118:

e2006478118. doi:10.1073/pnas.2006478118

Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher

EA, Moore KJ, Fernandez-Hernando C (2010) MiR-33 contributes to the

regulation of cholesterol homeostasis. Science 328: 1570–1573.

doi:10.1126/science.1189862

Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, Ray TD,

Sheedy FJ, Goedeke L, Liu X, et al (2011a) Inhibition of miR-33a/b in

non-human primates raises plasma HDL and lowers VLDL

triglycerides. Nature 478: 404–407. doi:10.1038/nature10486

Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM,

Rayner AJ, Chang AN, Suarez Y, et al (2011b) Antagonism of miR-33 in

mice promotes reverse cholesterol transport and regression of

atherosclerosis. J Clin Invest 121: 2921–2931. doi:10.1172/jci57275

Rong S, Cortes VA, Rashid S, Anderson NN, McDonald JG, Liang G, Moon YA,

Hammer RE, Horton JD (2017) Expression of SREBP-1c requires SREBP2-mediated generation of a sterol ligand for LXR in livers of mice. Elife

6: e25015. doi:10.7554/elife.25015

Rotllan N, Ramirez CM, Aryal B, Esau CC, Fernandez-Hernando C (2013)

Therapeutic silencing of microRNA-33 inhibits the progression of

atherosclerosis in Ldlr-/- mice–brief report. Arterioscler Thromb Vasc

Biol 33: 1973–1977. doi:10.1161/atvbaha.113.301732

Song Y, Liu J, Zhao K, Gao L, Zhao J (2021) Cholesterol-induced toxicity: An

integrated view of the role of cholesterol in multiple diseases. Cell

Metab 33: 1911–1925. doi:10.1016/j.cmet.2021.09.001

Tang CY, Man XF, Guo Y, Tang HN, Tang J, Zhou CL, Tan SW, Wang M, Zhou HD

(2017) IRS-2 partially compensates for the insulin signal defects in

IRS-1(–/–) mice mediated by miR-33. Mol Cell 40: 123–132.

doi:10.14348/molcells.2017.2228

Teratani T, Tomita K, Suzuki T, Oshikawa T, Yokoyama H, Shimamura K,

Tominaga S, Hiroi S, Irie R, Okada Y, et al (2012) A high-cholesterol diet

exacerbates liver fibrosis in mice via accumulation of free cholesterol

in hepatic stellate cells. Gastroenterology 142: 152–164.e10.

doi:10.1053/j.gastro.2011.09.049

Thaler H (1962) [The fatty liver and its pathogenetic relation to liver cirrhosis].

Virchows Archiv Pathol Anat Physiol Klin Med 335: 180–210. doi:10.1007/

bf02438705

Tomita K, Teratani T, Suzuki T, Shimizu M, Sato H, Narimatsu K, Okada Y,

Kurihara C, Irie R, Yokoyama H, et al (2014) Free cholesterol

accumulation in hepatic stellate cells: Mechanism of liver fibrosis

aggravation in nonalcoholic steatohepatitis in mice. Hepatology 59:

154–169. doi:10.1002/hep.26604

Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, Lee SP, Teoh

NC, Farrell GC (2011) Hepatic free cholesterol accumulates in obese,

diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology

141: 1393–403, 1403.e1-5. doi:10.1053/j.gastro.2011.06.040

Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, Landt CL,

Harrison SA (2011) Prevalence of nonalcoholic fatty liver disease and

nonalcoholic steatohepatitis among a largely middle-aged

population utilizing ultrasound and liver biopsy: A prospective study.

Gastroenterology 140: 124–131. doi:10.1053/j.gastro.2010.09.038

Wouters K, van Bilsen M, van Gorp PJ, Bieghs V, Lutjohann D, Kerksiek A, Staels

B, Hofker MH, Shiri-Sverdlov R (2010) Intrahepatic cholesterol

miR-33b inhibition improves NAFLD/NASH

Miyagawa et al.

influences progression, inhibition and reversal of non-alcoholic

steatohepatitis in hyperlipidemic mice. FEBS Lett 584: 1001–1005.

doi:10.1016/j.febslet.2010.01.046

Wree A, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, Hoffman HM,

Feldstein AE (2014) NLRP3 inflammasome activation results in

hepatocyte pyroptosis, liver inflammation, and fibrosis in mice.

Hepatology 59: 898–910. doi:10.1002/hep.26592

Xie X, Liao H, Dang H, Pang W, Guan Y, Wang X, Shyy JY, Zhu Y, Sladek FM (2009)

Down-regulation of hepatic HNF4α gene expression during

hyperinsulinemia via SREBPs. Mol Endocrinol 23: 434–443. doi:10.1210/

me.2007-0531

Yamaguchi K, Yang L, McCall S, Huang J, Yu XX, Pandey SK, Bhanot S, Monia BP,

Li YX, Diehl AM (2007) Inhibiting triglyceride synthesis improves

hepatic steatosis but exacerbates liver damage and fibrosis in obese

mice with nonalcoholic steatohepatitis. Hepatology 45: 1366–1374.

doi:10.1002/hep.21655

Yamamoto T, Yahara A, Waki R, Yasuhara H, Wada F, Harada-Shiba M,

Obika S (2015) Amido-bridged nucleic acids with small

hydrophobic residues enhance hepatic tropism of antisense

oligonucleotides in vivo. Org Biomol Chem 13: 3757–3765.

doi:10.1039/c5ob00242g

Yamasaki T, Horie T, Koyama S, Nakao T, Baba O, Kimura M, Sowa N, Sakamoto

K, Yamazaki K, Obika S, et al (2022) Inhibition of microRNA-33b

specifically ameliorates abdominal aortic aneurysm formation via

suppression of inflammatory pathways. Sci Rep 12: 11984. doi:10.1038/

s41598-022-16017-5

Yang H, Arif M, Yuan M, Li X, Shong K, Turkez H, Nielsen J, Uhlen M, Boren J,

Zhang C, et al (2021) A network-based approach reveals the

dysregulated transcriptional regulation in non-alcoholic fatty liver

disease. iScience 24: 103222. doi:10.1016/j.isci.2021.103222

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global

epidemiology of nonalcoholic fatty liver disease-Meta-analytic

assessment of prevalence, incidence, and outcomes. Hepatology 64:

73–84. doi:10.1002/hep.28431

Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J,

Bugianesi E (2018) Global burden of NAFLD and NASH: Trends,

predictions, risk factors and prevention. Nat Rev Gastroenterol

Hepatol 15: 11–20. doi:10.1038/nrgastro.2017.109

Zhang X, Rotllan N, Canfran-Duque A, Sun J, Toczek J, Moshnikova A, Malik S,

Price NL, Araldi E, Zhong W, et al (2022) Targeted suppression of

miRNA-33 using pHLIP improves atherosclerosis regression. Circ Res

131: 77–90. doi:10.1161/circresaha.121.320296

Zhao L, Chen Y, Tang R, Chen Y, Li Q, Gong J, Huang A, Varghese Z, Moorhead JF,

Ruan XZ (2011) Inflammatory stress exacerbates hepatic cholesterol

accumulation via increasing cholesterol uptake and de novo

synthesis. J Gastroenterol Hepatol 26: 875–883. doi:10.1111/j.14401746.2010.06560.x

License: This article is available under a Creative

Commons License (Attribution 4.0 International, as

described at https://creativecommons.org/

licenses/by/4.0/).

https://doi.org/10.26508/lsa.202301902

vol 6 | no 8 | e202301902

17 of 17

...